Pages that link to "Q34267910"
Jump to navigation
Jump to search
The following pages link to Recent developments in the field of tumor-inhibiting metal complexes. (Q34267910):
Displaying 50 items.
- Redox activation of metal-based prodrugs as a strategy for drug delivery (Q27025736) (← links)
- Sawhorse-type diruthenium tetracarbonyl complexes containing porphyrin-derived ligands as highly selective photosensitizers for female reproductive cancer cells (Q33412176) (← links)
- Electronic structural investigations of ruthenium compounds and anticancer prodrugs (Q33427427) (← links)
- Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery (Q33695863) (← links)
- A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases (Q33729793) (← links)
- Cytotoxic effects of the compound cis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells. (Q33848447) (← links)
- Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN'O] ligands as 26S proteasome inhibitors. (Q33884616) (← links)
- Unusual DNA binding modes for metal anticancer complexes (Q34071185) (← links)
- Ruthenium-based chemotherapeutics: are they ready for prime time? (Q34102818) (← links)
- Osmium(VI) complexes as a new class of potential anti-cancer agents (Q34157363) (← links)
- Quantitative bioimaging of platinum in polymer embedded mouse organs using laser ablation ICP-MS. (Q34915590) (← links)
- Metalloprobes: synthesis, characterization, and potency of a novel gallium(III) complex in human epidermal carcinoma cells (Q35147021) (← links)
- Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application. (Q35154374) (← links)
- Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents. (Q35598162) (← links)
- Osmium(IV) complexes with 1H- and 2H-indazoles: tautomer identity versus spectroscopic properties and antiproliferative activity (Q36103771) (← links)
- Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research. (Q36268494) (← links)
- Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects (Q36364465) (← links)
- A novel copper(II) complex identified as a potent drug against colorectal and breast cancer cells and as a poison inhibitor for human topoisomerase IIα. (Q36440601) (← links)
- New applications of old metal-binding drugs in the treatment of human cancer (Q36822739) (← links)
- CE in anticancer metallodrug research--an update (Q36936989) (← links)
- Synthesis, characterization, and preliminary in vitro studies of vanadium(IV) complexes with a Schiff base and thiosemicarbazones as mixed-ligands (Q37051991) (← links)
- Preliminary anti-cancer photodynamic therapeutic in vitro studies with mixed-metal binuclear ruthenium(II)-vanadium(IV) complexes. (Q37115673) (← links)
- Novel metals and metal complexes as platforms for cancer therapy (Q37137649) (← links)
- Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine (Q37169192) (← links)
- Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer (Q37687110) (← links)
- Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications (Q37997361) (← links)
- Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends (Q38052406) (← links)
- Metal complex interactions with DNA. (Q38271731) (← links)
- Interactions of cisplatin analogues with lysozyme: a comparative analysis (Q38624654) (← links)
- Anti-tumor activity and mechanism of apoptosis of A549 induced by ruthenium complex (Q38746692) (← links)
- Synthesis, X-ray structure and in vitro cytotoxicity studies of Cu(I/II) complexes of thiosemicarbazone: special emphasis on their interactions with DNA. (Q38904045) (← links)
- Protein ruthenation and DNA alkylation: chlorambucil-functionalized RAPTA complexes and their anticancer activity (Q38939454) (← links)
- An investigation on new ruthenium(II) hydrazone complexes as anticancer agents and their interaction with biomolecules (Q39024727) (← links)
- Gallium phosphinoarylbisthiolato complexes counteract drug resistance of cancer cells (Q39035304) (← links)
- Carbohydrate linked organotin(IV) complexes as human topoisomerase Iα inhibitor and their antiproliferative effects against the human carcinoma cell line (Q39047919) (← links)
- Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(III) and Ir(III) complexes (Q39097585) (← links)
- X-ray fluorescence imaging of single human cancer cells reveals that the N-heterocyclic ligands of iodinated analogues of ruthenium anticancer drugs remain coordinated after cellular uptake (Q39110547) (← links)
- Cellular uptake mechanisms of an antitumor ruthenium compound: the endosomal/lysosomal system as a target for anticancer metal-based drugs (Q39136843) (← links)
- Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: cytotoxic activity and human serum albumin binding mechanism (Q39177371) (← links)
- Mixed ligand palladium(II) complexes of 6-methoxy-2-oxo-1,2-dihydroquinoline-3-carbaldehyde 4N-substituted thiosemicarbazones with triphenylphosphine co-ligand: synthesis, crystal structure and biological properties (Q39302223) (← links)
- The anticancer activity and HSA binding properties of the structurally related platinum (II) complexes. (Q39343332) (← links)
- Cytotoxic salan-titanium(IV) complexes: high activity toward a range of sensitive and drug-resistant cell lines, and mechanistic insights (Q39409301) (← links)
- Ruthenium(II)/(III) complexes of 4-hydroxy-pyridine-2,6-dicarboxylic acid with PPh3/AsPh3 as co-ligand: impact of oxidation state and co-ligands on anticancer activity in vitro (Q39425500) (← links)
- Unexpected influence of stereochemistry on the cytotoxicity of highly efficient Ti(IV) salan complexes: new mechanistic insights (Q39444431) (← links)
- Major impact of N-methylation on cytotoxicity and hydrolysis of salan Ti(IV) complexes: sterics and electronics are intertwined (Q39483013) (← links)
- Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. (Q39517558) (← links)
- M2L4 coordination capsules with tunable anticancer activity upon guest encapsulation. (Q39528351) (← links)
- Interaction of rac-[M(diimine)3]2+ (M=Co, Ni) complexes with CT DNA: role of 5,6-dmp ligand on DNA binding and cleavage and cytotoxicity (Q39584594) (← links)
- In vitro cytotoxic evaluation of novel dichlorodiorgano[N-(2-pyridylmethylene)arylamine]tin(IV) derivatives in human tumor cell lines (Q39807589) (← links)
- Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells (Q39900189) (← links)